• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Afinitor - A Two-Pronged Attack Against Tuberous Sclerosis Complex - Product Image

Afinitor - A Two-Pronged Attack Against Tuberous Sclerosis Complex

  • Published: May 2012
  • 5 pages
  • GlobalData

Afinitor - A Two-Pronged Attack Against Tuberous Sclerosis Complex

Summary

GlobalData’s new alert, "Afinitor - A Two-Pronged Attack Against Tuberous Sclerosis Complex”, takes a look at the implications of the FDA’s recent approval of the drug for the treatment of angiomyolipomas, benign kidney tumors that affect a majority of people with this rare disease.

This is the second indication for Afinitor in this patient population; in October 2010, the drug was approved for the treatment of a rare type of brain tumor in tuberous sclerosis complex (TSC) patients called subependymal giant cell astrocytoma (SEGA). The approval of Afinitor in a second indication for TSC means that the product is now available to fulfill an important unmet treatment need in this patient population.

Scope

- Introduction and detail on TSC and its consequences, including angiomyolipomas and SEGA
- Description of EXIST-2, the pivotal Phase III trial that established the efficacy and safety of Afinitor in treating angiomyolipomas in TSC patients
- Limitations of surgery and other current treatments for TSC patients with angiomyolipomas and SEGA

Reasons READ MORE >

1
1

2 Introduction
3 Afinitor - A Two-Pronged Attack Against Tuberous Sclerosis Complex
3.1 Tuberous Sclerosis Complex
3.2 Unmet Treatment Need in TSC
3.3 Phase III Trial of Afinitor in TSC Patients with Angiomyolipomas
3.4 Conclusions
4 Appendix
4.1 Methodology
4.1.1 Coverage
4.1.2 Secondary Research
4.1.3 Primary Research
4.1.4 Expert Panel Validation
4.2 Contact Us
4.3 Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos